πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,413 results for β€œACE” Clear

  1. KIO-101

    KIORA PHARMACEUTICALS INC

    Dry Eye Disease

    phase 2 small molecule terminated

    1 trial

  2. KIO-104

    KIORA PHARMACEUTICALS INC

    Macular Edema

    phase 2 small molecule active

    1 trial

  3. KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)

    KIORA PHARMACEUTICALS INC

    Persistent Corneal Epithelial Defect

    phase 2 small molecule completed

    1 trial

  4. KIO-301

    KIORA PHARMACEUTICALS INC

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  5. KN046

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  6. KN046 （PD-L1/CTLA4 BsAbοΌ‰

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced HCC

    phase 2 small molecule terminated

    1 trial

  7. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Well-Controlled Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  8. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  9. KPL-404

    Kiniksa Pharmaceuticals International, plc

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  10. KPL-716

    Kiniksa Pharmaceuticals International, plc

    Chronic Idiopathic Urticaria

    phase 2 small molecule completed

    1 trial

  11. KPL-914

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule completed

    1 trial

  12. KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.

    Kymera Therapeutics

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  13. KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621

    Kymera Therapeutics

    Uncontrolled Moderate to Severe Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  14. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  15. KVD824

    Kalvista Pharmaceuticals (Ireland) Limited

    Angioedema, Hereditary, Types I and II

    phase 2 small molecule terminated

    1 trial

  16. KVD900

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 2 small molecule completed

    2 trials

  17. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  18. Kerendia 10 mg film coated tablets, Kerendia 20 mg film-coated tablets, Finerenone/Kerendia 10mg and 20mg Placebo equal to test product except active substance, Empagliflozin/Jardiance 10mg Placebo equal to test product except active substance, Jardiance 10 mg film-coated tablets

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  19. Ketamine

    Grace Therapeutics

    Obstetric Pain

    phase 2 small molecule completed

    1 trial

  20. LB-102

    LB PHARMACEUTICALS INC

    Bipolar I Disorder

    phase 2 small molecule active

    1 trial

  21. LB-208, LB-208

    AOP Orphan Pharmaceuticals GmbH

    Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

    phase 2 small molecule active

    1 trial

  22. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  23. LB54640

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule completed

    1 trial

  24. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources